PURPOSE: Pancreatic cancer still has one of the worst prognoses in gastrointestinal cancers with a 5-year survival rate of 5%, making it necessary to find markers or gene sets that would further classify patients into different risk categories and thus allow more individually adapted multimodality treatment regimens. In this study, we investigated the prognostic values of HIF1a, bFGF, VEGF, and PDGFA gene expressions as well as their interrelationships. EXPERIMENTAL DESIGN: Formalin-fixed paraffin-embedded tissue samples were obtained from 41 patients with pancreatic adenocarcinoma (age, 65; range, 34-85 years). After laser capture microdissection, direct quantitative real-time reverse transcription-polymerase chain reaction assays were performed in triplicates to determine HIF1a, PDGFA, VEGF, and bFGF gene expression levels. Multivariate Cox proportional hazards regression analysis was used to assess the impact of HIF1a gene expression on prognosis. RESULTS: HIF1a was significantly correlated to every gene we tested: bFGF (P = .04), VEGF (P = .02), and PDGFA (P = .03). Tumor size, P = .04, and high HIF1a mRNA expression (cutoff, 75th percentile) had a significant impact on survival, P = .009 (overall model fit, P = .02). High HIF1a expression had a sensitivity of 87.1% and a specificity of 55.6% for the diagnosis short (<6 months) versus long (6-60 months) survival. CONCLUSIONS: Measuring PDGFA, bFGF, and HIF1a expression may contribute to a better understanding of the prognosis of patients with pancreatic cancer and may even play a crucial role for the distribution of patients to multimodal therapeutic regimens. Larger studies including patients treated with actual chemotherapeutics seem to be warranted.
PURPOSE:Pancreatic cancer still has one of the worst prognoses in gastrointestinal cancers with a 5-year survival rate of 5%, making it necessary to find markers or gene sets that would further classify patients into different risk categories and thus allow more individually adapted multimodality treatment regimens. In this study, we investigated the prognostic values of HIF1a, bFGF, VEGF, and PDGFA gene expressions as well as their interrelationships. EXPERIMENTAL DESIGN:Formalin-fixed paraffin-embedded tissue samples were obtained from 41 patients with pancreatic adenocarcinoma (age, 65; range, 34-85 years). After laser capture microdissection, direct quantitative real-time reverse transcription-polymerase chain reaction assays were performed in triplicates to determine HIF1a, PDGFA, VEGF, and bFGF gene expression levels. Multivariate Cox proportional hazards regression analysis was used to assess the impact of HIF1a gene expression on prognosis. RESULTS:HIF1a was significantly correlated to every gene we tested: bFGF (P = .04), VEGF (P = .02), and PDGFA (P = .03). Tumor size, P = .04, and high HIF1a mRNA expression (cutoff, 75th percentile) had a significant impact on survival, P = .009 (overall model fit, P = .02). High HIF1a expression had a sensitivity of 87.1% and a specificity of 55.6% for the diagnosis short (<6 months) versus long (6-60 months) survival. CONCLUSIONS: Measuring PDGFA, bFGF, and HIF1a expression may contribute to a better understanding of the prognosis of patients with pancreatic cancer and may even play a crucial role for the distribution of patients to multimodal therapeutic regimens. Larger studies including patients treated with actual chemotherapeutics seem to be warranted.
Authors: P G Johnston; H J Lenz; C G Leichman; K D Danenberg; C J Allegra; P V Danenberg; L Leichman Journal: Cancer Res Date: 1995-04-01 Impact factor: 12.701
Authors: Karen H Lu; Andrea P Patterson; Lin Wang; Rebecca T Marquez; Edward N Atkinson; Keith A Baggerly; Lance R Ramoth; Daniel G Rosen; Jinsong Liu; Ingegerd Hellstrom; David Smith; Lynn Hartmann; David Fishman; Andrew Berchuck; Rosemarie Schmandt; Regina Whitaker; David M Gershenson; Gordon B Mills; Robert C Bast Journal: Clin Cancer Res Date: 2004-05-15 Impact factor: 12.531
Authors: A Giatromanolaki; M I Koukourakis; E Sivridis; H Turley; K Talks; F Pezzella; K C Gatter; A L Harris Journal: Br J Cancer Date: 2001-09-14 Impact factor: 7.640
Authors: Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines Journal: Neoplasia Date: 2009-02 Impact factor: 5.715
Authors: Justin G Wilkes; Brianne R O'Leary; Juan Du; Adrienne R Klinger; Zita A Sibenaller; Claire M Doskey; Katherine N Gibson-Corley; Matthew S Alexander; Susan Tsai; Garry R Buettner; Joseph J Cullen Journal: Clin Exp Metastasis Date: 2018-02-02 Impact factor: 5.150